In this article, we will discuss Idelalisib (Dosage Overview). So, let’s get started.
Relapsed Chronic Lymphocytic Leukemia
Idelalisib is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
Relapsed Follicular B-cell non-Hodgkin Lymphoma
Idelalisib is indicated for the treatment of patients with relapsed follicular B-cell nonHodgkin lymphoma (FL) who have received at least two prior systemic therapies.
Relapsed Small Lymphocytic Lymphoma
Idelalisib is indicated for the treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.
The recommended maximum starting dose of Idelalisib is 150 mg administered orally twice daily. Idelalisib can be taken with or without food. Tablets should be swallowed whole. Continue treatment until disease progression or unacceptable toxicity. The optimal and safe dosing regimen for patients who receive treatment longer than several months is unknown.